{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T19:31:32Z","timestamp":1747769492958},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,5,9]],"date-time":"2022-05-09T00:00:00Z","timestamp":1652054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,5,9]],"date-time":"2022-05-09T00:00:00Z","timestamp":1652054400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Glucocorticoids are the mainstay of treatment for pemphigus vulgaris (PV). However, the requirement of high doses for long durations often leads to serious adverse events. Methotrexate as an adjuvant has shown potential in retrospective studies but randomized trials are lacking. The objective of the study was to\u00a0assess the adjuvant potential of methotrexate in mucosal\/limited mucocutaneous PV. In this randomised prospective study, 44 patients with mucosal\/limited mucocutaneous PV were randomised (1:1) to receive either prednisolone 1\u00a0mg\/kg\/day (later fixed at a maximum dose of 60 mg\/day)\u00a0alone or with methotrexate 0.3\u00a0mg\/kg\/week for 9-months study period. Prednisolone dose was tapered once there was an 80% reduction in Pemphigus Disease Activity Index. Outcome measures were total cumulative dose of prednisolone, the proportion of patients achieving disease control, time taken for disease control and remission on minimal treatment, and adverse effects. No significant difference in the total cumulative dose of prednisolone among the groups was observed (p\u2009=\u20090.68). Disease control was achieved in 95.5% and 86.4% of patients in the prednisolone alone group, and prednisolone and methotrexate group respectively (p\u2009=\u20090.61). No statistically significant difference was observed among the groups with respect to the proportion of patients achieving remission, time taken for disease control and remission, and the number of adverse events. Our study showed no additional benefit of methotrexate to prednisolone in the treatment of mucosal\/limited mucocutaneous PV.<\/jats:p><jats:p><jats:bold>Trial registration:<\/jats:bold> CTRI\/2018\/07\/015002; Registered on 23\/07\/2018]; Trial Registered Retrospectively. <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/ctri.nic.in\/Clinicaltrials\/pdf_generate.php?trialid=24964&amp;EncHid=&amp;modid=&amp;compid=%27,%2724964det%27\">http:\/\/ctri.nic.in\/Clinicaltrials\/pdf_generate.php?trialid=24964&amp;EncHid=&amp;modid=&amp;compid=%27,%2724964det%27<\/jats:ext-link>.<\/jats:p>","DOI":"10.1038\/s41598-022-11387-2","type":"journal-article","created":{"date-parts":[[2022,5,9]],"date-time":"2022-05-09T10:03:05Z","timestamp":1652090585000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["A randomised clinical trial to assess the adjuvant potential of methotrexate to corticosteroids in mucosal or limited mucocutaneous pemphigus vulgaris"],"prefix":"10.1038","volume":"12","author":[{"given":"Khimit","family":"Jain","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vishal","family":"Thakur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanjeev","family":"Handa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neha","family":"Thakur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Shilpa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naresh","family":"Sachdeva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rahul","family":"Mahajan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dipankar","family":"De","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,5,9]]},"reference":[{"issue":"7","key":"11387_CR1","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1016\/j.rmed.2009.01.003","volume":"103","author":"SC Manson","year":"2009","unstructured":"Manson, S. C., Brown, R. E., Cerulli, A. & Vidaurre, C. F. The cumulative burden of oral corticosteroid side effects and the economic implications of steroid use. Respir. Med. 103(7), 975\u2013994. https:\/\/doi.org\/10.1016\/j.rmed.2009.01.003 (2009).","journal-title":"Respir. Med."},{"issue":"9","key":"11387_CR2","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.1111\/jdv.16752","volume":"34","author":"P Joly","year":"2020","unstructured":"Joly, P. et al. Updated S2K guidelines on the management of pemphigus vulgaris and foliaceus initiated by the European Academy of Dermatology and Venereology (EADV). J. Eur. Acad. Dermatol. Venereol. 34(9), 1900\u20131913. https:\/\/doi.org\/10.1111\/jdv.16752 (2020).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"issue":"6","key":"11387_CR3","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1002\/art.23721","volume":"59","author":"KG Saag","year":"2008","unstructured":"Saag, K. G. et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheumatol. 59(6), 762\u2013784. https:\/\/doi.org\/10.1002\/art.23721 (2008).","journal-title":"Arthritis Rheumatol."},{"issue":"5","key":"11387_CR4","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/j.jaad.2008.02.040","volume":"58","author":"A Gottlieb","year":"2008","unstructured":"Gottlieb, A. et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: Overview and guidelines of care for treatment with an emphasis on the biologics. J. Am. Acad. Dermatol. 58(5), 851\u2013864. https:\/\/doi.org\/10.1016\/j.jaad.2008.02.040 (2008).","journal-title":"J. Am. Acad. Dermatol."},{"issue":"4","key":"11387_CR5","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1111\/j.1365-2133.2009.09246.x","volume":"161","author":"HM G\u00fcrcan","year":"2009","unstructured":"G\u00fcrcan, H. M. & Ahmed, A. R. Analysis of current data on the use of methotrexate in the treatment of pemphigus and pemphigoid. Br. J. Dermatol. 161(4), 723\u2013731. https:\/\/doi.org\/10.1111\/j.1365-2133.2009.09246.x (2009).","journal-title":"Br. J. Dermatol."},{"issue":"1","key":"11387_CR6","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.clindermatol.2011.03.017","volume":"30","author":"BS Daniel","year":"2012","unstructured":"Daniel, B. S., Hertl, M., Werth, V. P., Eming, R. & Murrell, D. F. Severity score indexes for blistering diseases. Clin. Dermatol. 30(1), 108\u2013113. https:\/\/doi.org\/10.1016\/j.clindermatol.2011.03.017 (2012).","journal-title":"Clin. Dermatol."},{"issue":"5","key":"11387_CR7","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1111\/bjd.15930","volume":"177","author":"KE Harman","year":"2017","unstructured":"Harman, K. E. et al. British Association of Dermatologists\u2019 guidelines for the management of pemphigus vulgaris 2017. Br. J. Dermatol. 177(5), 1170\u20131201. https:\/\/doi.org\/10.1111\/bjd.15930 (2017).","journal-title":"Br. J. Dermatol."},{"issue":"5","key":"11387_CR8","first-page":"413","volume":"68","author":"N Mashkilleyson","year":"1988","unstructured":"Mashkilleyson, N. & Mashkilleyson, A. L. Mucous membrane manifestations of pemphigus vulgaris. A 25-year survey of 185 patients treated with corticosteroids or with combination of corticosteroids with methotrexate or heparin. Acta Derm. Venereol. 68(5), 413\u2013421 (1988).","journal-title":"Acta Derm. Venereol."},{"issue":"1","key":"11387_CR9","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1684\/ejd.2011.1611","volume":"22","author":"S Baum","year":"2012","unstructured":"Baum, S. et al. Methotrexate is an effective and safe adjuvant therapy for pemphigus vulgaris. Eur. J. Dermatol. 22(1), 83\u201387. https:\/\/doi.org\/10.1684\/ejd.2011.1611 (2012).","journal-title":"Eur. J. Dermatol."},{"issue":"4","key":"11387_CR10","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1111\/bjd.12474","volume":"169","author":"KD Tran","year":"2013","unstructured":"Tran, K. D., Wolverton, J. E. & Soter, N. A. Methotrexate in the treatment of pemphigus vulgaris: Experience in 23 patients. Br. J. Dermatol. 169(4), 916\u2013921. https:\/\/doi.org\/10.1111\/bjd.12474 (2013).","journal-title":"Br. J. Dermatol."},{"issue":"10","key":"11387_CR11","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1001\/archderm.135.10.1275","volume":"135","author":"TJ Smith","year":"1999","unstructured":"Smith, T. J. & Bystryn, J. C. Methotrexate as an adjuvant treatment for pemphigus vulgaris. Arch. Dermatol. 135(10), 1275\u20131276. https:\/\/doi.org\/10.1001\/archderm.135.10.1275 (1999).","journal-title":"Arch. Dermatol."},{"issue":"9","key":"11387_CR12","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1001\/archderm.1977.01640090084013","volume":"113","author":"WF Lever","year":"1977","unstructured":"Lever, W. F. & Schaumburg-Lever, G. Immunosuppressants and prednisone in pemphigus vulgaris: Therapeutic results obtained in 63 patients between 1961 and 1975. Arch. Dermatol. 113(9), 1236\u20131241 (1977).","journal-title":"Arch. Dermatol."},{"issue":"4","key":"11387_CR13","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1001\/archderm.1972.01620130023006","volume":"106","author":"WF Lever","year":"1972","unstructured":"Lever, W. F. Methotrexate and prednisone in pemphigus vulgaris. Therapeutic results obtained in 36 patients between 1961 and 1970. Arch. Dermatol. 106(4), 491\u2013497 (1972).","journal-title":"Arch. Dermatol."},{"issue":"2","key":"11387_CR14","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1111\/j.1365-2133.1970.tb15707.x","volume":"83","author":"S Jablonska","year":"1970","unstructured":"Jablonska, S., Chorzelski, T. & Blaszczyk, M. Immunosuppressants in the treatment of pemphigus. Br. J. Dermatol. 83(2), 315\u2013323. https:\/\/doi.org\/10.1111\/j.1365-2133.1970.tb15707.x (1970).","journal-title":"Br. J. Dermatol."},{"issue":"10","key":"11387_CR15","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1111\/j.1468-3083.2012.04717.x","volume":"27","author":"C Chams-Davatchi","year":"2013","unstructured":"Chams-Davatchi, C. et al. Randomized double blind trial of prednisolone and azathioprine, vs. prednisolone and placebo, in the treatment of pemphigus vulgaris. J. Eur. Acad. Dermatol. Venereol. 27(10), 1285\u20131292. https:\/\/doi.org\/10.1111\/j.1468-3083.2012.04717.x (2013).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"issue":"4","key":"11387_CR16","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1016\/j.jaad.2007.05.024","volume":"57","author":"C Chams-Davatchi","year":"2007","unstructured":"Chams-Davatchi, C. et al. Randomized controlled open-label trial of four treatment regimens for pemphigus vulgaris. J. Am. Acad. Dermatol. 57(4), 622\u2013628. https:\/\/doi.org\/10.1016\/j.jaad.2007.05.024 (2007).","journal-title":"J. Am. Acad. Dermatol."},{"issue":"7","key":"11387_CR17","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1111\/j.1468-3083.2011.04170.x","volume":"26","author":"D Ioannides","year":"2012","unstructured":"Ioannides, D., Apalla, Z., Lazaridou, E. & Rigopoulos, D. Evaluation of mycophenolate mofetil as a steroid-sparing agent in pemphigus: A randomized, prospective study. J. Eur. Acad. Dermatol. Venereol. 26(7), 855\u2013860. https:\/\/doi.org\/10.1111\/j.1468-3083.2011.04170.x (2012).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"issue":"8","key":"11387_CR18","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1038\/jid.2010.91","volume":"130","author":"S Beissert","year":"2010","unstructured":"Beissert, S. et al. Treating pemphigus vulgaris with prednisone and mycophenolate mofetil: A multicenter, randomized, placebo-controlled trial. J. Investig. Dermatol. 130(8), 2041\u20132048. https:\/\/doi.org\/10.1038\/jid.2010.91 (2010).","journal-title":"J. Investig. Dermatol."},{"issue":"4","key":"11387_CR19","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1001\/archdermatol.2011.56","volume":"147","author":"M Bigby","year":"2011","unstructured":"Bigby, M. A randomized controlled trial of the addition of mycophenolate mofetil or placebo to oral corticosteroids in the treatment of pemphigus vulgaris fails to demonstrate a significant difference in the primary outcome or quality of life. Arch. Dermatol. 147(4), 489\u2013491. https:\/\/doi.org\/10.1001\/archdermatol.2011.56 (2011).","journal-title":"Arch. Dermatol."},{"issue":"7","key":"11387_CR20","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1001\/archderm.136.7.868","volume":"136","author":"D Ioannides","year":"2000","unstructured":"Ioannides, D., Chrysomallis, F. & Bystryn, J. C. Ineffectiveness of cyclosporine as an adjuvant to corticosteroids in the treatment of pemphigus. Arch. Dermatol. 136(7), 868\u2013872. https:\/\/doi.org\/10.1001\/archderm.136.7.868 (2000).","journal-title":"Arch. Dermatol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-11387-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-11387-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-11387-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T03:08:03Z","timestamp":1669345683000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-11387-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,9]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["11387"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-11387-2","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,9]]},"assertion":[{"value":"8 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"7525"}}